中科生物(01237.HK)被美国裁反倾销和反补贴税令 保证金费率达54.43%
中科生物(01237.HK)公布,於1月22日美国国际贸易委员会裁定,美国的一个行业受到从中国进口的木线条和木制品(该等产品被美国商务部确定存在补贴和在美国以低於公允价值出售)的损害。
根据美国国际贸易委员会的肯定性裁定,商务部将对从中国进口的该等产品发出反倾销和反补贴税令。美国海关和边境保护局将向集团相关产品的进口商收取总计54.43%的现金存款。
集团旗下全资附属公司漳平木村被裁定其若干出口至美国之木制品之加权平均倾销率及补贴率分别为44.6%及20.56%,商务部将指示美国海关和边境保护局将向集团产品之进口商收取费率合共为54.43%之保证金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.